Saved report copy
Recorded
Leukemia vaccine succeeds in Phase 3 trial, adding to cancer advances
Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday that their vaccine for acute myeloid leukemia succeeded in a Phase 3 trial of 126 patients. Sellas said the vaccine cut the risk of death by 41 percent compared with other treatments, with median survival of 24 months versus 14.7 months; the trial involved patients in a second or later remission who could not receive a bone-marrow transplant. The result adds to a year of positive cancer-vaccine trial news, but full data are still pending, and Sellas plans to prepare an FDA approval submission in the first half of 2027.